GH Research (NASDAQ:GHRS) Price Target Raised to $35.00 at Cantor Fitzgerald

GH Research (NASDAQ:GHRS) had its price objective upped by research analysts at Cantor Fitzgerald from $25.00 to $35.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 57.59% from the company’s previous close.

Other equities analysts have also recently issued reports about the company. HC Wainwright boosted their price target on GH Research from $35.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Citizens Jmp dropped their target price on GH Research from $42.00 to $39.00 and set a “market outperform” rating for the company in a research note on Friday. Needham & Company LLC upped their target price on GH Research from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, March 6th. Guggenheim set a $34.00 target price on GH Research and gave the company a “buy” rating in a research note on Tuesday, March 10th. Finally, Royal Bank Of Canada upped their target price on GH Research from $33.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $41.00.

GH Research Stock Up 1.5%

NASDAQ GHRS opened at $22.21 on Friday. GH Research has a fifty-two week low of $9.52 and a fifty-two week high of $24.66. The stock has a market cap of $1.38 billion, a price-to-earnings ratio of -27.76 and a beta of 1.27. The business has a fifty day moving average of $17.03 and a 200-day moving average of $15.49.

GH Research (NASDAQ:GHRS) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). As a group, analysts anticipate that GH Research will post -1.52 EPS for the current year.

Institutional Investors Weigh In On GH Research

A number of institutional investors have recently added to or reduced their stakes in GHRS. JPMorgan Chase & Co. purchased a new stake in GH Research during the second quarter valued at about $79,000. BNP Paribas Financial Markets grew its position in GH Research by 165.4% during the second quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock valued at $207,000 after acquiring an additional 10,600 shares during the period. Osaic Holdings Inc. grew its position in GH Research by 63.6% during the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock valued at $75,000 after acquiring an additional 2,400 shares during the period. AdvisorShares Investments LLC grew its position in GH Research by 41.1% during the third quarter. AdvisorShares Investments LLC now owns 53,991 shares of the company’s stock valued at $772,000 after acquiring an additional 15,735 shares during the period. Finally, CenterBook Partners LP purchased a new stake in GH Research during the third quarter valued at about $2,376,000. Hedge funds and other institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.